发明申请
WO2006077414A1 PYRAZOLE DERIVATIVES FOR THE INHIBITION OF CDK' S AND GSK' S
审中-公开
用于抑制CDK和GSK'S的吡唑衍生物
- 专利标题： PYRAZOLE DERIVATIVES FOR THE INHIBITION OF CDK' S AND GSK' S
- 专利标题（中）： 用于抑制CDK和GSK'S的吡唑衍生物
-
申请号： PCT/GB2006/000191申请日： 2006-01-20
-
公开(公告)号： WO2006077414A1公开(公告)日： 2006-07-27
- 发明人: WYATT, Paul, Graham , BERDINI, Valerio , GILL, Adrian, Liam , TREWARTHA, Gary , WOODHEAD, Andrew, James , NAVARRO, Eva, Figueroa , O'BRIEN, Michael, Alistair , PHILLIPS, Theresa, Rachel
- 申请人： ASTEX THERAPEUTICS LIMITED , WYATT, Paul, Graham , BERDINI, Valerio , GILL, Adrian, Liam , TREWARTHA, Gary , WOODHEAD, Andrew, James , NAVARRO, Eva, Figueroa , O'BRIEN, Michael, Alistair , PHILLIPS, Theresa, Rachel
- 申请人地址： 436 Cambridge Science Park, Milton Road, Cambridge CB4 0QA GB
- 专利权人： ASTEX THERAPEUTICS LIMITED,WYATT, Paul, Graham,BERDINI, Valerio,GILL, Adrian, Liam,TREWARTHA, Gary,WOODHEAD, Andrew, James,NAVARRO, Eva, Figueroa,O'BRIEN, Michael, Alistair,PHILLIPS, Theresa, Rachel
- 当前专利权人： ASTEX THERAPEUTICS LIMITED,WYATT, Paul, Graham,BERDINI, Valerio,GILL, Adrian, Liam,TREWARTHA, Gary,WOODHEAD, Andrew, James,NAVARRO, Eva, Figueroa,O'BRIEN, Michael, Alistair,PHILLIPS, Theresa, Rachel
- 当前专利权人地址： 436 Cambridge Science Park, Milton Road, Cambridge CB4 0QA GB
- 代理机构： HUTCHINS, Michael, Richard
- 优先权： US60/646,217 20050121; GB0501480.8 20050122; GB0501748.8 20050127; US60/651,339 20050209
- 主分类号： C07D401/14
- IPC分类号： C07D401/14 ; A61K31/44 ; A61P35/00 ; A01N43/56
摘要：
The invention provides compounds of the formula (I), or salts, tautomers, N-oxides or solvates thereof wherein: R1 is selected from: (a) 2,6-dichlorophenyl; (b) 2,6-difluorophenyl; (c) a 2,3,6-trisubstituted phenyl group wherein the substituents for the phenyl group are selected from fluorine, chlorine, methyl and methoxy; (d) a group R0; (e) a group R a; (f) a group Rlb; (g) a group Rlc; (h) a group Rld; and 0) 2,6-difluorophenylamino ; wherein R )0υ, r R> llaa, T Rj I1bD, T R) I1cC, r R> Iidα, r R»2zaa, r R>22bD and RJ are as defined in the claims. The compounds have activity as inhibitors of cdk kinase (such as cdkl or cdk2) and glycogen synthase kinase-3 activity.
